Stockwinners Market Radar for February 27, 2024 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

20:42 EST Cathie Wood's ARK Investment bought 737K shares of Archer Aviation today

20:40 EST Cathie Wood's ARK Investment bought 169K shares of Roku today

19:16 EST Veru receives Nasdaq notification on delayed quarterly report - Veru announced that it received a delinquency notification letter from the Listing Qualifications staff of the Nasdaq Stock Market LLC on February 21, 2024 due to the company's non-compliance with Nasdaq Listing Rule 5250(c)(1) as a result of the company's failure to timely file its Quarterly Report on Form 10-Q for the fiscal quarter ended December 31, 2023. Nasdaq Listing Rule 5250(c)(1) requires listed companies to timely file all required periodic financial reports with the Securities and Exchange Commission. The Notice states that the company has 60 calendar days to submit to Nasdaq a plan to regain compliance with the Nasdaq Listing Rules. If Nasdaq accepts the company's plan, then Nasdaq may grant the company up to 180 calendar days from the prescribed due date for filing the Form 10-Q or until August 19, 2024, to regain compliance. If Nasdaq does not accept the company's plan, then the company will have the opportunity to appeal that decision to a Nasdaq Hearings Panel.

19:03 EST Allegiant reports January total system passengers fell 2% y/y - Allegiant reported preliminary passenger traffic results for January 2024. Total passengers fell 2.3% year-over-year in January to 1,176,117. RPMs fell 2.3% year-over-year, while ASMs rose 0.6%. Load factor for January was 80.7%, down from 83.2% in the same period last year. Total system passengers fell 2% year-over-year to 1,182,748.

19:01 EST Exelixis exec Haley sells 47,020 common shares - In a regulatory filing, Exelixis executive VP Patrick Haley disclosed the sale of 47,020 common shares of the company on February 23 at a price of $21.45 per share.

18:52 EST PureCycle Technologies reschedules Q4 earnings to March 6th - PureCycle Technologies "announced it has rescheduled the Company's fourth quarter 2023 update from February 29 to March 6 at 11:00 a.m. EST. The change is due to the Company's previously announced purchase of Ironton revenue bonds, expected to close by March 4, 2024, and the additional time needed to finalize the financial statements and related information included in the Company's Annual Report on Form 10-K."

18:10 EST Dole to sell 65% equity stake in Progressive Produce to PTF Holdings - Dole has announced that it has reached an agreement to sell its 65% equity stake in Progressive Produce to PTF Holdings, the parent company of Pacific Trellis Fruit. PTF Holdings is a portfolio company of Arable Capital Partners will receive gross cash proceeds of $120.25M from this sale. Progressive Produce, located in Los Angeles, California, is a grower, packer, and distributor of conventional and organic produce to the retail, wholesale and foodservice sectors in the U.S. and Canada. Founded in 1967, today the Company is one of California's premier produce companies with annual sales in excess of $400M. Progressive Produce is a subsidiary of Dole plc and is part of the Diversified Fresh Produce - Americas and Rest of World reporting segment. Post the completion of this transaction, the existing management team of Progressive Produce will remain with the enlarged business of Progressive Produce and Pacific Trellis Fruit and retain an ownership stake. The transaction is expected to close in March 2024, subject to the satisfaction of customary closing conditions. Net proceeds from the sale received by Dole are currently expected to be used primarily for debt reduction.

17:39 EST General Dynamics awarded $210.34M Army contract - General Dynamics was awarded a $210.34M hybrid contract for the purchase, warehousing, repair, issue, shipment, disposal, obsolescence management and configuration management of parts to support the Stryker Brigade Combat Team. Bids were solicited via the internet with one received. Work will be performed in Sterling Heights, Michigan, with an estimated completion date of February 28, 2030. FY24 Army working capital funds; and FY24 operation and maintenance, Army funds in the amount of $210.34M, were obligated at the time of the award. Army Contracting Command is the contracting activity.

17:19 EST California Resources sees FY24 capital program $300M-$340M - CRC's 2024 guidance estimates exclude the pending merger with Aera. The Company intends to update guidance after the transaction closes. CRC expects its total 2024 capital program $300M-$340M assuming normal operating conditions. Of this amount, $250M-$260M is related to oil and natural gas development, $30M-$40M is related to maintenance of one of its gas processing facilities and a power plant, both of which are located in CRC's Elk Hills field, $15M-$25M is for carbon management projects and $5M-$15M is for corporate and other activities. Through 2024, CRC expects to run a one rig program executing projects using existing permits. Subject to the availability of well permits, the Company expects to increase to a four rig program in the second half of 2024. The actual amount of spending related to oil and gas development under CRC's 2024 capital program will depend on a variety of factors. In particular, the rate and amount of this spending depends on its ability to obtain new well permits in the second half of the year.

17:08 EST Ovintiv sees FY24 total production 545MBOE/d-575MBO/d - Sees FY24 capital Investment $2.200B-$2.400B.

17:04 EST Blue Foundry Bancorp announces 1.2M share stock repurchase program - Blue Foundry Bancorp announced that it has adopted a program to repurchase up to 1,203,545 shares of its common stock, which is approximately 5% of its outstanding common stock. This is the company's fourth stock repurchase program since completing its mutual-to-stock conversion and related stock offering in July 2021. Since announcing its first stock repurchase program on July 20, 2022, the company has repurchased 5,409,022 shares. As of February 26, there were 46,736 shares remaining to be repurchased under the third plan. The fourth plan will commence immediately upon the completion of the third plan.

17:02 EST Vishay CFO Lori Lipcaman to resign, David McConnell to succeed - Vishay announced that its board has appointed David McConnell, senior VP -corporate treasurer and risk management, to the role of executive VP - CFO, replacing Lori Lipcaman who is resigning from that position. In addition, David Tomlinson, senior VP - corporate controller, has been promoted by the board to the newly created role of senior VP - chief accounting officer reporting to McConnell. The new positions of McConnell and Tomlinson will take effect on March 1.

16:48 EST Flywire jumps 20% to $29.50 after Q4 earnings beat, above-consensus FY24 outlook

16:46 EST Nutrien announces TSX approval for renewed share buyback program for up to 5% - Nutrien announced that the Toronto Stock Exchange has accepted Nutrien's notice to commence a normal course issuer bid to purchase outstanding common shares representing up to 5% of its issued and outstanding common shares.

16:41 EST Rayonier Advanced Materials, Verso execute MoU to explore eSAF - Rayonier Advanced Materials and Verso Energy have entered into a Memorandum of Understanding to explore e-fuels and specifically e-SAF or Sustainable Aviation Fuel from renewable resources. As part of the MoU, the companies will explore the feasibility of using the Biogenic Carbon Dioxide (Biogenic CO2) produced at RYAM's Tartas France plant along with Green Hydrogen to produce eSAF, a vital product needed to help reduce the world's rising greenhouse gases through Carbon Capture Utilization. The companies expect to qualify for grants from the French government to help fund the cost of this multi-year feasibility study. "We are excited to be partnering with Verso Energy on this endeavor," said De Lyle Bloomquist RYAM's President and Chief Executive Officer. "Combining the unique attributes of RYAM's Tartas plant with VERSO ENERGY's expertise in the development of renewable energy creates a great opportunity for the potential expansion of new sustainable fuels at the site."

16:37 EST eBay up 4% following Q4 report - Shares of eBay are up $1.86, or 4%, to $46.25 in after-hours trading.

16:34 EST Boston Beer announces CEO Burwick to retire, Spillane to succeed - The Boston Beer Company announced leadership changes effective April 1, 2024. Dave Burwick will retire as President and Chief Executive Officer and member of the Board of Directors, with Michael Spillane to assume the President and CEO role effective upon Burwick's retirement. Spillane is currently the lead director of The Boston Beer Company and has been a board member since 2016.

16:33 EST Civitas Resources announces share repurchase from NGP - Civitas Resources announced the execution of a definitive agreement to repurchase approximately 876 thousand shares of its common stock at a price of $64.54 per share from NGP Tap Rock Holdings, LLC and certain of its affiliates. The transaction was approved by the Company's Board of Directors, and the repurchase is expected to close in early March 2024. Following the transaction, NGP will no longer own any shares of Civitas. Civitas CEO Chris Doyle said, "Returning significant cash to shareholders is one of our strategic pillars as a Company. Over the past two years, we have returned over $1.5 billion to our owners, representing approximately a quarter of our current market cap, through share repurchases and dividends. Our current share price represents a compelling valuation, and this transaction efficiently facilitates NGP's exit from the stock. Utilizing our generated free cash flow, we will continue to be opportunistic in buying back our shares going forward, while also enhancing our balance sheet and paying a peer-leading dividend."

16:32 EST Rocket Lab unveils spacecraft bus lineup - Rocket Lab USA introduced its family of spacecraft buses, consolidating the custom designs Rocket Lab has developed for multiple customers and missions. "We've had the privilege of developing, launching, and operating spacecraft for a broad range of customers and they've all told us the same thing: They need reliable and highly capable spacecraft built quickly and affordably. Photon was the start, but the Rocket Lab spacecraft family has grown," said Rocket Lab founder and CEO Peter Beck. "We've developed a configurable spacecraft line that delivers high performance at scale, supported by an experienced team, technical maturity, a vertically-integrated supply chain, and advanced manufacturing, test and operations facilities. We've designed these spacecraft through close collaboration with our customers to support real missions at constellation scale. The hard development work is done, and now these spacecraft are available as off-the-shelf products, or they can be further customized to meet specific mission requirements."

16:29 EST Par Pacific CEO William Pate to retire, Will Monteleone to assume CEO role - Par Pacific Holdings announced a leadership transition effective as of the company's May 2024 shareholders' meeting. William Pate will retire as CEO at the upcoming annual shareholders' meeting after eight years as leader of the rapidly growing energy company. The company's board unanimously appointed Will Monteleone to become the company's President and CEO. Monteleone has been with Par Pacific for more than a decade and has served in several leadership positions for the company. Pate and Monteleone will each continue to serve as members of the company's board.

16:26 EST Bumble to cut 350 jobs - Bumble announced that it intends to reduce its global workforce by approximately 350 roles to better align its operating model with future strategic priorities and to drive stronger operating leverage. "We expect to incur approximately $20 million to $25 million of non-recurring charges, consisting primarily of employee severance, benefits, and related charges for impacted employees, the majority of which will be recognized in the first two quarters of 2024," the company said.

16:23 EST Syndax sees FY24 research and development expenses $240M-$260M - Sees FY24 operating expenses $355M-$375M, which includes an estimated $43M in non-cash stock compensation expense. The Company believes that it has sufficient cash runway to fund its research, clinical development and commercial operations through 2026.

16:22 EST Syndax Q1 research and development expenses $56M-$62M - Sees Q1 total operating expenses $82M-$88M.

16:20 EST Luminar sees achieving quarterly revenue run rate mid-$30M range for 2024 - Luminar said, "We expect to achieve a quarterly run rate of revenue in the mid-$30M range following our expected SOP and ramp with Volvo in 2H'24. This would equate o an annualized run rate of ~$140M in revenue. We expect to end the year with greater than$150M in Cash & Liquidity, including our recently obtained credit line. We believe our liquidity profile is sufficient to provide at least two years of runway from today. As we prioritize optimizing our Mexico facility and de-risking the start of series production for Volvo, we expect most of our pre-launch financial metrics in Q1'24 to be roughly similar to Q4'23: In line to slightly lower revenue; some improvement to our Non-GAAP gross loss; higher change in cash & liquidity as we build working capital to support Volvo SOP."

16:18 EST Universal Health sees FY24 CapEx $850M-$1B

16:17 EST Inter Parfums raises annual dividend 20% to $3.00 per share - Atwood also announced, "Our Board of Directors approved a 20% increase in the annual dividend to $3.00 per share. The decisive factors motivating our board's decision include our robust financial standing, promising growth opportunities, and commitment to delivering value to our shareholders." The next quarterly cash dividend of $0.75 per share is payable on March 29, 2024 to shareholders of record on March 15, 2024.

16:15 EST Compass sees FY24 adjusted operating expense $855M-$875M - Expects to be free cash flow positive for full year 2024

16:11 EST XP Inc. announces new share repurchase program - XP Inc. announced that its board of directors has approved a new share repurchase program, which aims to neutralize future shareholder dilution due to the vesting of Restricted Stock Units from the Company's long-term incentive plan. The Company proposes to undertake a share repurchase program pursuant to which the Board can annually, in each calendar year, approve the repurchase by the Company of a number of Class A Common Shares equal to the number of RSUs that have vested or will vest during the current calendar year. Under the approved repurchase program for 2024, XP may repurchase up to 2,500,000 Class A Common Shares within the period commencing on February 28, 2024, and ending on December 27, 2024. Such purchases shall occur in the open market, based on prevailing market prices, or in privately negotiated transactions, depending upon market conditions. XP's board of directors will review the repurchase program periodically and may authorize adjustments to its terms and size or suspend or discontinue the repurchase program. XP expects to utilize its existing cash to fund repurchases made under the repurchase program.

16:10 EST Imax seesFY24 total Adjusted EBITDA margin in High 30's percent - Sees FY24 IMAX gross box office similar to 2023, and system Installations 120 to 150 Systems.

16:08 EST Xencor expects cash to fund operations into 2027 - Based on current operating plans, Xencor expects to end 2024 with between $475 million and $525 million in cash, cash equivalents and marketable debt securities, and to have cash to fund research and development programs and operations into 2027.

16:08 EST Viridian Therapeutics expects cash to fund operations into second half of 2026 - The company believes that its current cash, cash equivalents, and short-term investments, including proceeds from the ATM and January financing, will be sufficient to fund its operations into the second half of 2026.

16:06 EST Revolve Group sees FY24 gross margin 52.5%-53.0% - Sees FY24 fulfillment expenses 3.3%-3.5% of net sales; selling and distribution expenses 17.8%-18.0% of net sales; marketing expenses 16.0%-16.2% of net sales; general and administrative expenses $130M-$133M; and effective tax rate 24%-26%.

16:04 EST Axon provides long-term outlook - "Looking ahead, we remain confident in our ability to scale globally, to penetrate new customer verticals and to introduce new products that drive highly profitable revenue growth as we progress on our mission to protect life. We believe our future opportunities will enable us to drive solid top and bottom-line growth, generate significant cash flow, and create meaningful value for our shareholders. Last year at this time, we provided a three-year target model for 2025, including a revenue target of $2 billion, implying a 20% revenue compound annual growth rate, and a 25% Adjusted EBITDA margin target. Given our strong revenue performance in 2023 and new 2024 guidance, which we are proud to provide above our outlook from this time last year, along with our progress on margin expansion, we are updating our long-term framework. Beyond 2024, we expect to achieve continued 20% or greater compound annual revenue growth and continue to target Adjusted EBITDA margins of approximately 25% as we continue to balance investing for growth and delivering strong profitability. We also remain committed to delivering strong cash generation with Adjusted Free Cash Flow conversion on Adjusted EBITDA of at least 60% by 2025. In addition, we remain focused on reducing annual dilution related to stock-based compensation and we continue to target average annual dilution from stock compensation expense of approximately 3% for 2025 and beyond."

15:54 EST Sizzle Acquisition Corp trading halted, volatility trading pause

14:35 EST Tegna names Tom Cox chief growth officer - Tegna announced that Tom Cox has been promoted to the newly created position of chief growth officer reporting to president and CEO Dave Lougee, effective immediately. As chief growth officer, Cox will be responsible for leading efforts to accelerate TEGNA's existing digital businesses as well as identify new opportunities. He will also lead TEGNA's technology and digital product divisions. Previously, Cox was president of Premion and senior vice president, business development at TEGNA. Daniel Spinosa, currently chief financial officer at Premion, has been promoted to president and will report to Cox. "As we look to the future, Tom's extensive experience leading transformative transactions and scaling early to mid-stage businesses will be instrumental as we chart our future trajectory," said Dave Lougee, president and CEO, TEGNA.

12:40 EST Lotus Technology Inc trading halted, volatility trading pause

12:00 EST Perrigo falls -16.0% - Perrigo is down -16.0%, or -$5.16 to $27.01.

12:00 EST BigBear.ai rises 25.5% - BigBear.ai is up 25.5%, or 64c to $3.12.

12:00 EST Hims & Hers rises 34.4% - Hims & Hers is up 34.4%, or $3.52 to $13.78.

11:48 EST Hut 8 Corp. commences construction of new mining site in Culberson County - Hut 8 Corp. announced that it has commenced construction of its newest digital asset mining site in Culberson County, Texas. With construction underway, the Company expects to bring miners online at the site in Q2 2024. The Culberson County site creates the optionality for the Company to expand its self-mining fleet or to transition existing self-mining activity from Granbury, Texas and Kearney, Nebraska to the site. The site is expected to have up to approximately 3.6 EH/s of self-mining capacity if current generation miners are deployed. Based on current energy price forecasts, the Company expects that its cost to mine a Bitcoin at the Culberson County site will be approximately 30% lower than its cost to mine a Bitcoin through its hosted miners at Granbury, Texas and Kearney, Nebraska. "The Culberson County project exemplifies Hut 8's focus on operating excellence," said Hut 8 CEO Asher Genoot. "Our in-house development team enables us to build quickly and cost-effectively. Compared to the benchmark of approximately $460,000 per MW set by recent acquisitions in the area, our all-in cost to design and build the Culberson County site is expected to be less than $275,000 per MW. This represents a savings of more than 40%, or approximately $18,500,000 in upfront development costs per every 100 MW of expansion. For the Culberson County site specifically, this means that we expect to build the site for $17,300,000 or less, instead of approximately $29,000,000."

10:52 EST Arisz Acquisition Corp trading resumes

10:48 EST Adtran: Long-term growth drivers 'fully' intact

10:43 EST Volvo Group Venture Capital invests in Zacua Ventures - Volvo Group Venture Capital AB has invested in Zacua Ventures Builders Fund I, L.P. - a global venture capital fund focused on early-stage technology for the construction industry. Zacua Ventures was established in 2022 and focuses on start-ups working with emerging technologies that address decarbonization in the construction industry. The Zacua fund invests in companies working with at least one of three primary investment themes: productivity, sustainability, and urbanization. Operating globally in North America, Latin America, Europe, and Asia, Zacua Ventures has access to the latest technology development in each region and its sub-sectors of construction technology, creating possibilities to invest in the most impactful solutions in for example sustainability, robotics and digitization.

10:32 EST Bank of America testing AI, has identified 10-15 use cases

10:32 EST Bank of America feels 'very good' about guidance - Comments taken from the UBS Financial Services Forum.

10:01 EST Janux Therapeutics trading resumes

10:00 EST Lowe's sees 2024 gross margins 'roughly flat' - Says "perfectly positioned" to grow and take market share in the long-term. Says not forecasting improvement in demand trends in 2024, but expects comparisons to be easier in second half. Expects ticket to hold up in 2024, sees pullback in transactions. Says more focused on space productivity vs. opening new stores.

10:00 EST Perrigo falls -13.6% - Perrigo is down -13.6%, or -$4.37 to $27.80.

10:00 EST Norwegian Cruise Line rises 12.3% - Norwegian Cruise Line is up 12.3%, or $1.97 to $17.90.

10:00 EST Hims & Hers rises 25.3% - Hims & Hers is up 25.3%, or $2.59 to $12.84.

09:56 EST Janux Therapeutics trading halted, volatility trading pause

09:47 EST Unity falls -13.7% - Unity is down -13.7%, or -$4.54 to $28.50.

09:47 EST Perrigo falls -15.2% - Perrigo is down -15.2%, or -$4.88 to $27.29.

09:47 EST Norwegian Cruise Line rises 13.1% - Norwegian Cruise Line is up 13.1%, or $2.08 to $18.02.

09:43 EST Dogness Internationa trading halted, volatility trading pause

09:41 EST Heartland Financial sees FY24 NIM stable at 3.5% - Sees loan growth 6%-8%, deposit growth 5%-7%, with an effective tax rate of 24%. Sees CET1 approaching 11.5%-12% by year-end. Guidance taken from Investor Day presentation slides.

09:39 EST Crown Electrokinetics says EK film team solved 12-inch mastering challenge - Crown Electrokinetics issued a letter to its shareholders, which read in part, "As many of you know, Crown has been working towards achieving a path to develop its embossing master for 12-inch-wide film. The path that Crown embarked on quite some time ago involved combining its internal techniques with the efforts of its European vendor. I'm keenly aware that Crown has missed deadlines in the past, this communication is not meant to be an excuse, but rather an explanation. Crown is attempting to create something that has never been done before, technical discovery can often be inherently unpredictable. Crown has had many factors that delayed our mastering development, but with the delays came critical learning eventually leading to progress. I am happy to announce that Crown's EK film team has solved the 12-inch mastering challenge for its "Gen 1" smart window insert. While some minor refining is required, including some tooling replication, Crown is in a great position to start shipping first product in small quantities in July...Going forward, Crown expects to provide more details on product capabilities, timing, customer wins as well as pricing and expected revenue and margins. A little over a year ago, Crown made its first investment in the Fiber Optics construction market. The last 13 months have provided some hard lessons and taught Crown a great deal about not only the market, but also how to operate within it. Many of you were curious as to why Crown decided to initially move in this direction. While Crown was always confident that it could solve the mastering issue in its EK Film division, Crown could not ultimately predict exactly when that would occur. The decision to buy directional drilling assets in the fiber optics construction market in January of last year was done so in an effort to generate eventual revenue and earnings, benefiting shareholders while Crown reached the recent technological milestone described earlier. I am happy to let you know that Crown is generating revenue in both our Arizona market and in our recently announced Florida market. While Crown started servicing the Arizona market with its micro trenching and horizontal direction drilling, Crown has also been given opportunities to grow outside of the Arizona market. The opportunity in Florida is a direct result of the efforts of our recently announced President of Crown Fiber, Corey Boaz. Corey has not only positively affected Crown's immediate revenue generation but has also brought to Crown an operating model that allows Crown to be cash flow positive on a project from day one. Corey also has market credibility and connections that has allowed him to build a significant pipeline of revenue generating projects. This pipeline, leveraged within his proven business model, is expected to generate positive cashflow in the near term. Analyzing the recently announced Florida opportunity, Crown has been awarded 300 miles of horizontal directional drilling as its first phase with estimated revenue of $11 million. Crown has already begun the work and, promisingly, have been meeting and surpassing production and margin targets every day. Crown expects it can scale production without the need to significantly hire more people, rather carefully selecting and leveraging known subcontractors at a guaranteed rate of production. This outsourced model allows Crown to lock in returns based on daily production and by adding more subcontractors, Crown can generate more revenue and earnings. With the work on the initial 300 miles underway, there remains an additional 800 miles that Crown expects to be awarded later.Crown announced in January that it would be providing revenue guidance in the February time frame. With all of the recent progress and developments, I have delayed this slightly. I am now expecting to have an investor call on Friday, March 8th. Please look for a subsequent announcement providing the details for our shareholders who would like to attend."

09:34 EST Creative Realities, IceBox Network partner for in-store advertising - Creative Realities announced its partnership with IceBox Network, a new ad-based network concept under digital out-of-home technology provider Digi Point Media, to revolutionize retail advertising with exclusive digital display placements atop ice suppliers across retail stores for the first time. This collaboration will leverage Creative Realities' ReflectView CMS and Reflect AdLogic platform as well as integrated programmatic platforms to quickly distribute content, track ads and provide automatic ad placement. With exclusive rights to install digital displays atop merchandising units of the largest ice provider in the country, IceBox Network has the ability to reach approximately 85,000 end points with merchandisers spread across 37 states, with the potential of creating one of the most extensive and widespread advertising networks available.

09:31 EST Lowe's 'bullish' on medium to long-term outlook for housing industry - Says near term outlook uncertain due to macro economic factors. Expects Pro sales to remain strong, pressure on DIY. Expects 1H24 comp sales to remain under pressure, then improve in 2H24.

09:21 EST Tyler Technologies to provide Cannabis Licensing to the Commonwealth of Kentucky - Tyler Technologies announced it has signed an agreement with the Commonwealth of Kentucky to implement Tyler's Cannabis Licensing solution to support the regulation of its medical cannabis program. The Commonwealth of Kentucky signed Senate Bill 47 in March 2023, which established parameters and guardrails around the legalization of medical cannabis. The Bill will go into effect Jan. 1, 2025, and Tyler's software will be instrumental in preparing for the launch of the Kentucky Medical Cannabis Program. As part of that launch, the Cabinet for Health and Family Services, CHFS, will ensure that Kentuckians suffering from serious medical conditions have safe, affordable access to medical cannabis, achieved via commitment to evidence-based practices, transparency, outreach, and education.

09:19 EST JPMorgan sees Q1 markets revenue down 5%-10% y/y - CFO Jeremy Barnum is speaking at the UBS Financial Services Forum.

09:17 EST Knight-Swift CEO David Jackson steps down, Adam Miller succeeds - Knight-Swift announced that Adam Miller has been promoted to CEO and Andrew Hess has been promoted to CFO. Miller had been serving as the company's CFO and president of Swift Transportation, while Hess had been serving as senior VP of M&A and senior VP of finance for Swift Transportation. David Jackson has stepped down as CEO and a member of the board of directors following a successful nine years as CEO and 13 years as president.

09:15 EST Dolphin Entertainment's The Digital Dept. establishes YA division - The Digital Dept. announces the establishment of a new Young Adult division dedicated to nurturing the creativity of young creators across Gen Z and Gen Alpha in the digital sphere. The establishment of this YA division heralds a strategic partnership with The Osbrink Agency, renowned for more than three decades for its representation of the leading teen and young adult talent in the entertainment industry.

09:13 EST LPL Financial supports launch of Continuity Private Wealth - LPL Financial announced that financial advisors James Debuque and Timothy Baltz have launched a new independent practice, Continuity Private Wealth, through affiliation with LPL Financial's supported independence model, LPL Strategic Wealth Services. They reported having served approximately $1 billion in advisory, brokerage and retirement plan assets and join LPL from Merrill Lynch. Based in Doylestown, Pa., the seasoned advisors partnered nearly 15 years ago to build out a private wealth team focused on helping affluent clients manage sophisticated estate and tax planning, as well as investment issues. They are joined by longtime Chief Operating Officer Wendy A. Fratrik, CRPC, Client Relationship Manager Nicole Ferrara and Wealth Management Associate Lisa Baltz, all whom share their passion for helping people connect pieces of their financial lives to work toward their goals.

09:11 EST Lowe's says DIY customers 'remain cautious' with home improvement spend - Says DIY customers "hesitant" to spend on big ticket items. Expects DIY demand to "remain under pressure." Says Pro customers' report their backlogs in line with last year, and cautiously optimistic on their ability to close leads. Says consumer "financially healthy," but prefers to spend on services. Comments taken from Q4 earnings conference call.

09:08 EST Hilton teams with AutoCamp to offer 'elevated outdoor lodging experiences' - Hilton announced a new exclusive partnership with premier outdoor hospitality company AutoCamp to offer Hilton guests an experience that blends the spirit of an iconic outdoor adventure with the hospitality and design-forward thinking of a boutique hotel, in spectacular settings that include properties adjacent to popular national parks. AutoCamp stays will be bookable on Hilton's direct channels in the coming months, giving Hilton guests direct access to outdoor hospitality that goes beyond "glamping." Hilton Honors members will be able to earn and redeem Points and enjoy exclusive member benefits while experiencing sought-after locations across the United States, such as Yosemite, Joshua Tree and Russian River in California; Zion, Utah; Cape Cod, Mass.; and Catskills, N.Y.; with Asheville, N.C. and Sequoia, Calif., opening this summer and Hill Country, Texas, in 2025.

09:07 EST Disguise announces extension of rights for Halo franchise - Disguise, the costume division of JAKKS Pacific, announces the extension of its partnership with 343 Industries as a global costume partner for the Halo franchise. This renewal marks a significant milestone in their collaborative journey, with Disguise slated to continue designing, marketing, manufacturing, and distributing costumes and costume accessories worldwide for Halo fans of all ages. Tara Cortner, President, and GM of Disguise, Inc., expressed her excitement about the continued collaboration, remarking, "Disguise boasts the largest portfolio of gaming costumes in the industry, and Halo has consistently ranked among our top sellers. We are thrilled to extend our partnership with 343 Industries, a testament to the enduring appeal of the characters in the Halo franchise." Cortner further emphasized the universality of Halo's appeal, noting, "As we continue to grow internationally, we see that the Master Chief is a much beloved character for kids, adults and fans across the world. Our designs continue to refresh and reflect updates to the characters in each iteration of the game from the first release through Halo Infinite. We look forward to showing fans more innovation and creativity for years to come."

09:06 EST Scilex annoucnes acceptance of abstract for poster, oral presentation at AAPM - Scilex Holding announced acceptance of an abstract for poster and oral presentation at the 2024 Annual Meeting of the American Academy of Pain Medicine, AAPM, which will take place on March 7-10, 2024 in Scottsdale, Arizona. Titled: Decreased Opioid Utilization with Lidocaine Topical System 1.8% Compared to Lidocaine 5% Patch: A Retrospective Claims Analysis: In this retrospective analysis of OPTUM claims data, researchers evaluated over 6,000 patients with neuropathic pain who were treated with either ZTlido or a generic lidocaine 5% patch and were also receiving an opioid. The study demonstrated a greater proportion of patients treated with ZTlido were able to either decrease or discontinue opioids compared to patients treated with a generic lidocaine 5% patch. In addition, patients treated with ZTlido had a more significant reduction in opioid dose relative to a generic lidocaine 5% patch. Regardless of the type of neuropathic pain, ZTlido was associated with a greater opioid-sparing effect than a generic lidocaine 5% patch. Title: Retrospective Claims Analysis of Decreased Healthcare Visits and Costs with Lidocaine Topical System 1.8% Compared to Lidocaine 5% Patch: In a retrospective analysis of over 889,000 patients, we used Symphony Health claims data to evaluate the impact of ZTlido versus lidocaine 5% patch on healthcare resource utilization, including emergency room visits, office/clinic visits, outpatient visits, and pain procedures. Across the studied care settings, treatment with ZTlido was associated with either a reduction or insignificant increase in healthcare resource utilization, while lidocaine 5% patch was associated with consistently and significantly large increases in healthcare resource utilization. These results are consistent with and confirm early reported data from another retrospective claims analysis.

09:05 EST AGBA 'strategically positioned' to capitalize on Hong Kong's return to growth - The company said, "The year 2023 posed significant macro-economic challenges for Hong Kong and China, particularly in relation to the Chinese real estate and financial markets. As an open economy heavily reliant on tourism, exports, and financial markets, Hong Kong faced a difficult year. However, there are now emerging signs of a recovery in the macro environment for both China and Hong Kong. The annual Chinese New Year celebrations in Hong Kong this year witnessed a record number of visitors from Mainland China, indicating an upswing in spending, including on financial products and services. Alongside these cyclical tailwinds, Hong Kong is experiencing structural growth driven by demographic factors and the increasing demand for its products and services from the Greater Bay Area. AGBA Group Holding is strategically positioned to capitalize on Hong Kong's return to growth. The challenges faced in 2023 prompted successful changes to AGBA's business model, resulting in increased focus and efficiency. The implementation of significant cost-cutting measures is expected to reduce normalized operating expenses to a level for strong growth and profitability. With its enhanced and streamlined business model, AGBA is well-prepared for growth in 2024. Growth will be further supported by the recent securing of substantial funds through a successful equity private placement in February 2024, in addition to completing and planning asset sales of non-core activities. These strategic initiatives have positioned AGBA as a formidable player in the market and facilitated the establishment of exciting and successful new partnerships. These collaborations are anticipated to further enhance AGBA's growth potential and consolidate its position as an industry leader. Various factors contributing to a substantial decline in AGBA's share price since its listing on Nasdaq in 2022. There now exists a notable disconnect between the current share price and the underlying business value. Given the improved macro environment and the growth prospects stemming from AGBA's refined business model, closing this valuation gap presents significant upside potential for existing and new shareholders."

09:04 EST Virtu Financial announces strategic collaboration with ClearingBid - Virtu Financial announced a strategic engagement with ClearingBid, the world's first IPO investing network. Under the terms of the agreement, ClearingBid's proprietary IPO network will leverage Virtu ITG Net's scaled connectivity platform. All brokers and financial institutions that rely on Virtu's connectivity to complete millions of transactions every day will now be able to place orders for IPO shares using the same order entry systems as secondary market limit orders."Virtu is one of the industry's largest trading providers with premier processing and fulfillment capabilities," noted Matt Venturi, ClearingBid CEO and Founder. "By providing investors with seamless order entry and accessibility, and having Virtu ITG Net serve as our preferred network service provider, ClearingBid moves one step closer in our mission to enhance an often inefficient and opaque IPO process. Our partnership with Virtu further supports ClearingBid's ability to leverage today's securities industry infrastructure and order entry protocols to meet the growing demand for access to IPO investing. The shared vision, to create a new IPO investing standard while driving further industry transparency, will help to expand investment opportunities for retail and institutional investors alike."

09:03 EST Veon launches digital-first brand ROX in Pakistan - VEON announces that Jazz, its digital operator in Pakistan, is launching ROX, a new mobile service brand to serve the digital natives of the country with an integrated lifestyle experience. ROX is designed to appeal to the digital-first generation of Pakistan and provides a range of digital lifestyle services through a dedicated mobile app. Launched with a slogan "Vibe Hai" which means "Feel the Vibe", ROX offers several "Vibe" bundles with which customers will enjoy easy onboarding and digital subscriptions from Jazz and partners. Among the offers are Jazz services including streaming app Tamasha, games app GameNow, music app Bajao as well as food delivery, ride hailing, discount aggregator and ticket booking from partners.

09:01 EST 111, Inc. receives withdrawal of going private proposals - 111 , Inc. has received a notice dated Feburary 27 on behalf of the consortium comprising Gang Yu, co-founder and co-chairman of the company, Junling Liu, co-founder, co-chairman and CEO of the company and certain other investors, stating that the consortium would withdraw its preliminary non-binding going private proposal dated September 9, 2022 and preliminary non-binding going private proposal dated October 29, 2022. The Consortium will formally terminate further negotiation with the special committee of the company's board of directors regarding the transactions as contemplated by the Proposals.

08:58 EST Blackstone completes acquisition of Rover Group - Rover Group (ROVR) announced the completion of its acquisition by private equity funds affiliated with Blackstone (BX) in an all-cash transaction valued at approximately $2.3 billion. The transaction was previously announced on November 29, 2023 and was approved by Rover stockholders at Rover's special meeting of stockholders held on February 22, 2024. With the completion of the acquisition, Rover stockholders are entitled to receive $11.00 in cash for each share of Rover common stock they owned immediately prior to the closing. Rover's common stock has ceased trading and will be delisted from the Nasdaq Stock Market. Reference Link

08:52 EST OLB Group announces market relaunch of Black Wireless - OLB Group announces the market launch of two wireless phone provider resellers to the unbanked sector. Black Wireless, an AT&T-compatible prepaid phone service reseller, and Mango Mobile, a T-Mobile-compatible prepaid phone service, was "soft launched" to validate the market demand and the signup authentication process before this national market launch. The two cell phone service provider networks target the rapidly growing unbanked and budget-savvy consumer sector. The subsidiary, Black Wireless, utilizes both an eSIM and physical SIM delivery to customers. An eSIM is a virtual SIM card that is downloaded directly into the customer's phone. The customer can download the eSIM immediately and be activated within minutes. With the newer eSIM-compatible phones, a customer can use twenty separate phone lines on the same device.

08:50 EST SOBR Safe signs TraTek Monitoring Services as client - SOBR Safe announced that TraTek Monitoring Services is adopting SOBRsafe's technology for immediate use in support of its family law and voluntary pre-trial clients. Based in British Columbia, Canada TraTek has made an initial multi-unit purchase of both SOBRcheck and SOBRsure devices. TraTek intends to utilize its regional sales manager model to deploy SOBRsafe solutions nationwide. In addition, TraTek is exploring an application for the technology in the Canadian over-the-road trucking market.

08:48 EST Ensysce Biosciences receives positive Nasdaq listing determination - Ensysce Biosciences has received notice from The Nasdaq Stock Market, as described in a decision dated February 26, 2024, that the Company may continue its listing on The Nasdaq Capital Market tier with an extension to May 13, 2024 in order to demonstrate compliance with the equity requirement in Listing Rule 5550(b)(1).

08:47 EST Gulf Island Fabrication sells excess property for $8.5M in proceeds - Gulf Island Fabrication has completed the sale of certain excess property that was part of the Company's facilities located in Houma, Louisiana for net cash proceeds of approximately $8.5 million.

08:45 EST Lixte Biotechnology announces presentation of LB-100 - LIXTE Biotechnology announced that Rene Bernards, PhD, professor of molecular carcinogenesis at Utrecht University in Amsterdam and head of molecular carcinogenesis at the Netherlands Cancer Institute, will present new pre-clinical data on LIXTE's lead compound, LB-100, at the Joint Conference of European and American Associations for Cancer Research this week in Dublin, Ireland. Dr. Bernards is also a member of LIXTE's Board of Directors. In his presentation, "Unexpected, but Highly Synergistic Combinations for Cancer Therapy," Dr. Bernards will present data on how stress imposed onto colon cancer cells by LB-100 drives cancer cells to evolve to less cancerous behavior. "The findings underscore the unique and what we believe to be exciting features and mechanism of action of LIXTE's PP2A inhibitor, LB-100," said Dr. James Miser, LIXTE's Chief Medical Officer. "While conventional cancer drugs aim to inhibit oncogenic signaling, which tends to drive cancer cells into more aggressive behavior, LB-100 does exactly the opposite, overloading oncogenic signaling, and thereby forcing cells to downregulate the signals that are characteristic for cancer cells. As a consequence, cancer cells are forced to evolve to a less aggressive behavior."

08:44 EST Rigetti Computing, Riverlane announce participation in project led by ORNL - Riverlane and Rigetti announced their participation in a project led by the US Department of Energy's Oak Ridge National Laboratory, ORNL, to explore the challenges of integrating a quantum computer with a large-scale, supercomputing centre. To assess the viability of integrating quantum computers into HPC environments, the project partners will build the first-ever benchmarking suite for measuring the performance of a joint HPC + Quantum system. Riverlane, Rigetti and ORNL will publish the results of the project, sharing the key learnings about interoperability issues and performance from interfacing early quantum devices with HPC-infrastructure. This will include key learnings about whether quantum computers should be installed on-site or can be successfully used through remote access.

08:41 EST Blackstone completes acquisition of Rover - Rover Group announced the completion of its acquisition by private equity funds affiliated with Blackstone in an all-cash transaction valued at approximately $2.3 billion. The transaction was previously announced on November 29, 2023 and was approved by Rover stockholders at Rover's special meeting of stockholders held on February 22, 2024. With the completion of the acquisition, Rover stockholders are entitled to receive $11.00 in cash for each share of Rover common stock they owned immediately prior to the closing. Rover's common stock has ceased trading and will be delisted from the Nasdaq Stock Market.

08:40 EST GigaCloud expands supplier diversity, introduces new markets to B2B ecommerce - GigaCloud Technology announced that suppliers from new product origins in Colombia, Mexico, and Turkey have joined its B2B ecommerce platform, GigaCloud Marketplace. This addition further diversifies the platform's product offerings and optimizes global supply chain management. Three global suppliers have joined the GigaCloud Marketplace as new 3P sellers, expanding the seller base in new markets and introducing new SKUs to the platform. Colombia-based Plasticos MQ will introduce a variety of home products and outdoor furniture, Krill International Furniture from Mexico will make available an exclusive collection for sale on the GigaCloud Marketplace, and Naar Rug, with 45 years of carpet crafting history in Turkey, will add high-quality rug selections under the store name DECART RUG on the platform.

08:38 EST CISO Global appoints Brett Chugg to board of directors - CISO Global has named Brett Chugg to its Board of Directors. Chugg most recently served as senior managing director at Koch Disruptive Technologies, a venture and growth equity investment group at Koch Industries.

08:37 EST Inuvo announces ability to measure performance of Netflix ad campaigns - Inuvo announced its ability to deliver access to and measure the performance of Netflix ad campaigns across programmatic channels. The opportunity to leverage Netflix inventory combined with IntentKey's analytics features presents a truly unique value proposition for advertisers. Because third party pixels are restricted on Netflix, measuring campaign performance is extremely difficult. Inuvo's integrated Performance Spend Analysis uses machine learning to determine the optimal spend levels across campaigns and channels including Netflix inventory. The just-in-time results are accessible through the IntentKey Insights Dashboard providing advertisers with out-of-the-box performance visibility into their campaigns.

08:36 EST Macy's says currently evaluating Arkhouse Management candidates

08:35 EST Adeia renews multi-yaer IP license agreement with Paramount - Adeia (ADEA) announced that Paramount (PARA) has renewed a multi-year license agreement for Adeia's media intellectual property, IP, portfolio. Paramount+ continues to be one of the fastest growing streaming services and in the third quarter of 2023 Paramount+ reported over 63M subscribers. "The mix of subscription and advertising-based streaming services offered by Paramount provides consumers with an array of options for engaging with digital entertainment in a constantly changing economic landscape," said Dr. Mark Kokes, Adeia's chief licensing officer and general manager, media.

08:33 EST Oatly Group announces launch of flavored oatmilk creamers - Oatly Group announced the launch of Oatly Oatmilk Creamers in the US, a new beverage innovation that joins the brand's growing fluid portfolio aimed at inspiring increased use in coffee occasions. "At Oatly, we're passionate about all things coffee, and naturally saw an opportunity to bring our expertise to the diverse and popular creamer category," said Leah Hoxie, SVP of Innovation, Oatly North America. "As a company, we're committed to converting cow's milk drinkers into oatmilk buyers, so we're excited to now offer fantastic, flavored creamers to people looking for a sweeter, more indulgent coffee experience. No matter consumers' dietary preferences, it's our hope that all coffee drinkers can agree with our belief that our new Oatly Creamers deliver superior taste and functionality - just like the rest of our oatmilk portfolio."

08:32 EST Cumulus Media announces exchange offer, consent solicitation - Cumulus Media announced that its subsidiary, Cumulus Media New Holdings, has commenced an offer to exchange any and all of the Issuer's outstanding 6.750% Senior Secured First-Lien Notes due 2026 for new 8.750% Senior Secured First-Lien Notes due 2029 to be issued by the Issuer, upon the terms of and subject to the conditions set forth in the confidential offering memorandum and consent solicitation statement dated February 27, 2024.

08:32 EST Hepsiburada appoints Hakan Karadoan as CEO of Logistics - Hepsiburada appointed Hakan Karadoan to the role of CEO of Logistics, effective March 25. Karadoan will lead Hepsiburada's overall logistics operations, including warehousing, fulfillment, and last-mile delivery services for both on-platform and off-platform customers. Effective from March 31, Chief Logistics Officer Mehmethan Yallagoz has decided to step down from his role to pursue other business interests. Prior to joining Hepsiburada, Hakan Karadoan was the General Manager of Amazon Turkiye Operations during which he, among other things, led the launch of Amazon's Turkiye Operations in 2018. Mr. Karadoan also has 22 years of management experience from General Electric and its predecessors.

08:31 EST Mainz Biomed to showcase ColoAlert at Gynecology Conference - Mainz Biomed announces its participation as an exhibitor at the esteemed Gynecology Congress in Stuttgart, Germany, on March 1st. This engagement signifies the company's commitment to advancing colorectal cancer, CRC, screening through their innovative diagnostic solution ColoAlert and highlights the pivotal role of gynecologists in the early detection of this prevalent disease.

08:29 EST A-Mark Precious Metals closes acquisition of LPM Group - A-Mark Precious Metals has closed its previously announced transactions with AMS Holding. This transaction included the acquisition of LPM Group Limited. A-Mark has acquired 100% of the issued and outstanding equity interests of LPM from AMS for a total upfront consideration of $41.9 million, consisting of $37.9 million in cash and $4.0 million of A-Mark common stock. At the close of the transaction, LPM had a tangible net worth of $11.9 million inclusive of net cash and precious metals inventories. AMS has the potential to earn up to an additional $37.5 million in cash based on achievement of certain Earnings before Interest, Taxes, Depreciation, and Amortization targets for 2024, 2025 and 2026. A-Mark's affiliate, Pinehurst Coin Exchange, Inc. (Pinehurst), one of the nation's largest distributors of modern certified coins of which A-Mark owns 49.0%, has acquired all the assets of ModernCoinMart from AMS for $5.5 million. MCM is one of the fastest growing dealers in the U.S. and ships to many international destinations. As part of the asset purchase, Pinehurst has acquired $3.0 million of inventory, along with MCM's customer list, brand name and related intellectual property. A joint venture consisting of A-Mark, Pinehurst and Stack's Bowers Numismatics, LLC, an affiliate of A-Mark, has acquired a common equity interest in AMS equivalent to 10% of the total, fully diluted common equity interests in AMS for $6.19 million. As part of the transaction, A-Mark CEO Greg Roberts has joined the AMS board of directors.

08:26 EST Earlyworks selected as co-creation partner for MetaMe - Earlyworks has been selected as a co-creation partner for MetaMe, a meta-communication service utilizing cutting-edge technology from NTT DOCOMO, one of Japan's largest cell phone operators.

08:25 EST Snail innovates development pipeline with AI Technology - Snail announced its strategic integration of AI technology into its game development process, marking a significant step in gaming innovation. By consistently evaluating the latest AI tools, Snail Games is introducing pivotal advancements in game development. The Company is transforming the art pipeline with cutting-edge text-to-3D model technology and pioneering the generation of resources and biomes on a planetary scale.

08:24 EST Blade Air Mobility opens investor Q&A platform ahead of Q4 release - Blade Air Mobility announced the opening of the shareholder Q&A platform to be used for its upcoming conference call to discuss the financial results for the fiscal fourth quarter ended December 31, 2023. Blade will conduct the call at 8:00am ET on Tuesday, March 12, 2024. Starting today, any shareholder will be able to submit and upvote questions to management of the Company. To submit questions ahead of the conference call, please visit the Say platform here. Shareholders using brokers that are integrated with Say can also participate directly through their investing app or broker's website.

08:23 EST Nogin divests fulfillment operations, partners with Cart.com - As part of its strategic shift, Nogin has also divested its fulfillment operations and has partnered with Cart.com as its preferred provider. This move allows Nogin to fully concentrate its resources on advancing its technology stack and enhancing its offerings for D2C and Amazon/marketplace management, while ensuring its customers continue to receive exceptional fulfillment services through Cart.com.

08:22 EST Nogin names Shoab Khan as CTO, Munan Xue as CMO, Chaim Sash as CPO - In a pivotal move to drive e-commerce innovation, Nogin has expanded its leadership team by welcoming three key senior executives: Shoab Khan as Chief Technology Officer, Munan Xue as Chief Marketing Officer, and Chaim Sash as Chief Product Officer. Each brings a wealth of experience and expertise to Nogin, positioning the company to lead the charge in e-commerce technology and service offerings. These executives report to Shahriyar Rahmati, Nogin's COO and CFO.

08:21 EST Macy's expects consumer to remain under pressure

08:20 EST Nogin realigns business to focus on next-gen technology investments - Nogin announced a significant realignment of its business strategy to focus more intensely on next-generation technology investments in artificial intelligence, analytics, multi-channel e-commerce, full lifecycle digital marketing, and world-class UX/Design. This strategic refocus is aimed at bolstering Nogin's core capabilities in delivering advanced e-commerce solutions to its partners and customers.

08:19 EST BriaCell files formal complaints with FINRA, CIRO on alleged illegal trading - BriaCell Therapeutics provides an update to the previously announced investigation of alleged illegal trading activity of its publicly traded securities. Upon external forensic analysis of data from various industry sources consistently demonstrating significant settlement share imbalances, and after discussions with 12 individual prime brokers for clarification of these imbalances, the Company has filed formal complaints with the Financial Industry Regulatory Authority and the Canadian Investment Regulatory Organization/ The Company will continue to work with regulatory authorities to combat illegal manipulative trading activities and will provide further updates on this investigation as they become available.

08:18 EST Tonix Pharmaceuticals announces results from clinical PK study of Tonmya - Tonix Pharmaceuticals announced positive results from its clinical pharmacokinetic, PK, bridging study of Tonmya in healthy adult male and female ethnic Japanese and Chinese volunteers. Results indicate that key pharmacokinetic parameters of cyclobenzaprine are comparable in ethnic Japanese and Chinese volunteers to Caucasian volunteers from a prior PK study. Tonmya was generally well tolerated in the ethnic Japanese and Chinese healthy volunteers. The company expects these data to fulfill the requirement for a bridging study, and to support regulatory filings for clinical studies in Japan and China where cyclobenzaprine is a new chemical entity. "This bridging study is an important first step as we begin evaluating the potential for approval and marketing Tonmya in Japan and China. The results show a similar pharmacokinetic profile in ethnic Japanese and Chinese volunteers with a Caucasian comparator group," said Seth Lederman, M.D., Chief Executive Officer of Tonix Pharmaceuticals. "As a result, we believe that these data, with supporting results recently reported from the positive Phase 3 RESILIENT study, are the only clinical data needed to support regulatory filings in Japan and China."

08:15 EST Horizon Aircraft says global investors expect eVTOL passenger routes by 2026 - New Horizon Aircraft publishes new global research that indicates global investors are anticipating the first commercial passenger routes of electric Vertical Takeoff and Landing aircraft to be operational in the next few years as the Future Air Mobility market continues to advance rapidly. Its global study with senior executives at leading investment firms in Japan, the US, Canada, Europe, the Middle East, and Asia responsible for more than $1.787 trillion assets under management reveals increasing optimism about the Urban Air Mobility market with two in five investors stating they think the first commercial UAM routes will be operational by 2026. Only 4% of professional investors believe the debut date for commercial passenger routes will extend beyond 2030. This study also revealed that nearly all professional investors agree that the growing demand for better and more efficient transportation systems across the world, combined with the need to reduce the environmental impact caused by more vehicles on the road and advances in technology improving the safety and viability of eVTOLs, will drive improvements in the regulatory framework and fuel investment in the sector over the next five years. Only 1% of investors did not agree that overcoming any potential obstacles would inevitably see increased investment in the eVTOL market. Horizon is targeting the future production of a manned seven-seat capacity hybrid electric eVTOL called the Cavorite X7 which includes room for a pilot and six passengers. It has been developed in response to demand from potential customers in the medevac, business aviation and commercial cargo sectors.

08:13 EST Minerva receives complete response letter from FDA for NDA for roluperidone - Minerva Neurosciences announced that the U.S. Food and Drug Administration, FDA, has issued a Complete Response Letter, CRL, to the Company's New Drug Application, NDA, for roluperidone for the treatment of negative symptoms in patients with schizophrenia. In the CRL, the FDA cited the following clinical deficiencies: Although one study demonstrated statistical significance on the primary efficacy endpoint, it is insufficient on its own to establish substantial evidence of effectiveness. The NDA submission lacks data on concomitant antipsychotic administration. The NDA submission lacks data needed to establish that the change in negative symptoms of schizophrenia with roluperidone treatment was clinically meaningful. The submitted safety database included an inadequate number of subjects exposed to roluperidone at the proposed dose for at least 12 months. To address these deficiencies, the FDA stated that Minerva must submit at least one additional positive, adequate, and well-controlled study to support the safety and effectiveness of roluperidone for the treatment of negative symptoms. Minerva must also provide additional data to demonstrate the safety and efficacy of roluperidone co-administered with antipsychotic medications, to support that observed effect on negative symptoms with roluperidone treatment corresponds to a clinically meaningful change, and to demonstrate the long-term safety of the proposed dose.

08:12 EST Amneal in licensing agreement with Zambon Biotech for IPX203 - Amneal Pharmaceuticals announced that it has entered into an exclusive licensing agreement with Zambon Biotech SA, part of the Zambon group for IPX203 in the European Union, United Kingdom, and Switzerland. IPX203 is a novel, oral formulation of carbidopa/levodopa ,CD/LD, extended-release capsules for the treatment of Parkinson's disease that is under review with the U.S. Food and Drug Administration. Zambon will seek regulatory approval and commercialize IPX203 in Europe. Financial terms of the agreement were not disclosed. Zambon is a privately held multinational chemical-pharmaceutical company founded in Italy in 1906. The company continues to be managed by the family of the original founder. Zambon has extensive presence in the European neurology space, having launched and commercialized XADAGO safinamide, which is used as add on to LD to treat fluctuating PD patients. IPX203 is expected to complement their existing portfolio and PD focus in Europe, where XADAGO is a registered trademark of Zambon SpA. "We believe IPX203 can improve the lives of the more than 10 million people worldwide living with Parkinson's disease. It has been a strategic goal of Amneal to ensure that not only U.S. patients but also Parkinson's patients worldwide have access to our products. Zambon, a family-owned business with whom we share a long-term vision and commitment toward patient communities, is the right partner to extend the reach of IPX203 to Europe," said Chirag and Chintu Patel, Co-Chief Executive Officers at Amneal.

08:10 EST Brera Holdings announces accelerated investment in Brera Tchumene, ESG goals - Brera Holdings (BREA) is pleased to announce that the strategic acquisition of Manchester United (MANU) stock last year, which has seen a remarkable 70% increase in value, has accelerated its investment into one of the Company's professional football teams, Brera Tchumene FC, based in Mozambique. This move underscores Brera Holdings' commitment to its Environmental, Social, and Governance, ESG, strategy, focusing on social impact and inclusivity in the world of professional football. The investment in Brera Tchumene FC is not merely a financial venture but a strategic move to foster economic growth and talent development in Mozambique. The Company's vision for football goes beyond the traditional transfer market, aiming to cultivate talent through bottom-up nurturing, offering opportunities to those who might otherwise be overlooked due to their socioeconomic status and other challenges. In alignment with this vision, Brera Holdings is thrilled to announce the appointment of Vasco Imparato as the new CEO of Brera Tchumene FC.

08:09 EST PetVivo approved to dual list on Upstream - PetVivo Holdings announced its approval to dual list its shares on Upstream, a MERJ Exchange market and global securities trading app. Trading becomes available on Upstream on March 5, 2024 at 10:00am ET under the ticker symbol "PETV."

08:08 EST Denali Therapeutics expects cash runway to extend into 2028 - Cash, cash equivalents, and marketable securities were approximately $1.03 billion as of December 31, 2023. For the full year 2024, Denali anticipates its operating expenses will be less than or equal to those in 2023 based on prioritization of its portfolio. With the anticipated proceeds from the PIPE financing, Denali expects the company's cash runway to extend into 2028.

08:06 EST Hormel Foods names Katie Clark as Chief Communications Officer - Hormel Foods announced Katie Clark has been appointed to the role of senior vice president and chief communications officer. Prior to joining Hormel Foods, Clark served as vice president of communications for Mattress Firm. She joined the company in 2020, leading internal communications, public relations, media relations, crisis and issues management, executive communications and social impact.

08:02 EST Clearmind Medicine submits three additional international patent applications - Clearmind Medicine (CMND) has submitted three additional patent applications under the international Patent Cooperation Treaty, as part of its ongoing collaboration with SciSparc Ltd. (SPRC). The patent applications refer to novel proprietary compositions of 3,4-Methylenedioxymethamphetamine, Ibogaine, and Ketamine, each with Palmitoylethanolamide, the active ingredient of SciSparc's proprietary CannAmide. These applications were previously filed as provisional patent applications with the United States Patent and Trademark Office. Overall, as part of this collaboration, 8 other patent applications have been filed by Clearmind with the USPTO for various combinations, 3 of them for the combination of SciSparc's PEA with Clearmind's MEAI compound for the treatment of alcohol use disorder, treatment of cocaine addiction and treatment of obesity and its related metabolic disorders. In addition, seven patent applications were filed under the international PCT.

07:56 EST Eli Lilly, Novo Nordisk shares fall after Viking Therapeutics obesity results

07:54 EST Viking Therapeutics Phase 2 GLP-1 study meets primary, secondary endpoints - Viking Therapeutics announced top-line results from the company's Phase 2 clinical trial of VK2735, a dual agonist of the glucagon-like peptide 1 and glucose-dependent insulinotropic polypeptide receptors in development for the potential treatment of various metabolic disorders such as obesity. The Phase 2 VENTURE trial successfully achieved its primary endpoint and all secondary endpoints, with patients receiving VK2735 demonstrating statistically significant reductions in body weight compared with placebo, the company said in a statement. Additionally, the study showed VK2735 treatment to be safe and well tolerated with the majority of treatment emergent adverse events being categorized as mild or moderate, it added. Based on these findings, Viking intends to meet with the FDA and discuss next steps in the development of VK2735. Patients receiving weekly doses of VK2735 demonstrated statistically significant reductions in mean body weight after 13 weeks, ranging up to 14.7% from baseline. Patients receiving VK2735 also demonstrated statistically significant reductions in mean body weight relative to placebo, ranging up to 13.1%. All doses of VK2735 also demonstrated statistically significant differences relative to placebo on the key secondary endpoint assessing the proportion of patients demonstrating at least 10% weight loss. Up to 88% of patients in VK2735 treatment groups achieved greater than or equal to 10% weight loss, compared with 4% for placebo.

07:50 EST Virpax announces settlement of l itigation with Sorrento and Scilex - Virpax Pharmaceuticals announced that it has entered into a term sheet to settle the litigation with the Company Sorrento Therapeutics Sorrento and Scilex Pharmaceutical The term sheet sets forth the principal terms of a mutual release and settlement agreement to be entered into by the Company and the Plaintiffs. However, if the parties fail to do so by or before March 1, 2024, the term sheet will become binding. As part of the settlement, the parties have agreed to a cash payment from Virpax to the Plaintiffs of $3.5M by March 1, and $2.5M by July 1, 2024, to settle all claims against Virpax. Additionally, Virpax will pay the plaintiffs royalties of 6% of annual net sales of products developed from drug candidates Epoladerm , Probudur or Envelta until the expiration of the last-to-expire valid patent claim and the expiration of any period of regulatory exclusivity. Each party releases all claims against the other party and neither party admits liability for any claim including those asserted in the lawsuit. Plaintiff's release of Virpax is conditioned upon Virpax making its initial payment. "I am pleased that we were able to bring this litigation to a satisfactory conclusion," stated Gerald Bruce, CEO of Virpax Pharmaceuticals. "We are now able to fully focus all of our efforts on the development of our drug product candidates as well as the Investigational New Drug Applications for our two lead programs."

07:48 EST Genmab, AbbVie announce FDA priority review for sBLA - Genmab (GMAB) and AbbVie (ABBV) announced the FDA granted priority review for the supplemental Biologics License Application, or sBLA, for epcoritamab-bysp, a T-cell engaging bispecific antibody administered subcutaneously, for the treatment of adult patients with relapsed or refractory follicular lymphoma after two or more lines of systemic therapy.

07:42 EST ARway signs deal with AMANAH TEKNOLOGIA for AR navigation - ARway.ai announced a new deal with AMANAH TEKNOLOGIA, located in Kuwait City, Kuwait. They are another ARway.ai partner, leading technology company and system integrator that provides innovative products to enhance the way businesses and people interact with technology; software development, cloud hosting, e-commerce and marketing. This deal encompasses a project to prototype mobile application for hospitals that integrates with EMR systems and acts as a digital concierge for visitors and staff. The prototype will be tested at the Dar AlShifa Hospital in Kuwait, which will leverage the ARwayKit SDK to provide AR navigation and immersive educational experiences throughout the entire facility. This ensures the hospital journey is as easy and seamless as possible.

07:39 EST Virpax Pharmaceuticals announces 1-for-10 reverse stock split - Virpax Pharmaceuticals announced that it will effect a 1-for-10 reverse stock split of its common stock, par value $0.001 per share, that will become effective at 12:01 a.m. Eastern Time on March 1. The company's common stock will continue to trade on Nasdaq under the symbol (VRPX) and will begin trading on a split-adjusted basis when the Nasdaq opens on March 1.

07:32 EST Theratechnologies announces FDA RTF regarding sBLA for Trogarzo - Theratechnologies announced that the United States Food and Drug Administration, FDA, has issued a refusal to file letter, RTF, regarding the Company's supplemental Biologics License Application, sBLA, for an intramuscular method of administration for the maintenance dose of Trogarzo. The sBLA filing was announced on January 2, 2024. Upon preliminary review, the FDA determined that the sBLA was not sufficiently complete to permit a substantive review. The RTF states that the sBLA did not contain the data required to establish the pharmacokinetic bridge between the IM and the intravenous infusion route of administration of Trogarzo. "While we are disappointed to receive this letter from the FDA, we were aware that the approval of this sBLA for Trogarzo IM administration could be challenging based on the results shared in October 2023 from the TMB-302 study, even though viral suppression was maintained throughout the study," said Christian Marsolais, Ph.D., Senior Vice President and Chief Medical Officer at Theratechnologies. "We will now assess our options regarding this application."

07:23 EST Laser Photonics appoints Carlos Gonzalez to board of directors - Laser Photonics announced that Carlos Gonzalez has been appointed independent director and chairman of its Audit Committee. Before joining Laser Photonics as a chairman and independent director, Gonzalez held several financial and management roles in support of manufacturing, energy and international trade companies such as Global Pangermex, Unified Energy Solutions Inc. and Sfinkx Corporation.

07:21 EST Acurx's ibezapolstat granted end of Phase 2 meeting by FDA, EMA SME designation - Acurx announced that an EOP2 meeting has been granted by FDA to discuss the overall Phase 3 clinical and non-clinical development plan to support an NDA filing for ibezapolstat for the treatment of CDI. The company submitted its Meeting Request earlier this month following successful completion of ibezapolstat's Phase 2 clinical trial. On February 14, the FDA granted an EOP2 meeting which confirms adequate information was provided to warrant this type of meeting. Additionally, the company was granted SME designation by the European Medicines Agency on February 15, which allows Acurx to benefit from fee incentives and other support from the EMA for conduct of required clinical trials for ultimate EU Marketing Authorization. The SME designation was established by EMA to promote innovation and the development of new medicinal products by smaller companies. Companies with SME status are eligible to receive financial incentives as well as administrative and regulatory support through national and regional level programs.

07:19 EST Engie North America announces $1B tax equity financing - ENGIE North America recently completed more than $1bn of Tax Equity financing, through separate agreements with three banks, J.P. Morgan, Goldman Sachs and BNP Paribas. The financing pertains to a portfolio of recently commissioned renewable projects in the U.S. The overall portfolio consists of 6 projects across ERCOT, MISO and SPP, including 950 MW of solar and 353 MW of wind capacity. The aggregate 1.3 GW of these renewable projects represents one of the largest Tax Equity financing arrangements for ENGIE North America so far.

07:17 EST Veradigm provides update on financial restatement process - Veradigm announced that the company does not expect to have filed its Annual Report on Form 10-K for the year ended December 31, 2022, or its Quarterly Reports on Form 10-Q for the quarters ended March 31, 2023, June 30, 2023 and September 30, 2023, by February 27, the deadline that Nasdaq has given the company to regain compliance with Nasdaq Listing Rule 5250(c)(1). The company anticipates it will receive a delisting notice from Nasdaq on February 28 and that its common stock will be suspended from trading on Nasdaq while Nasdaq proceeds with delisting. The company plans to provide additional information regarding the anticipated delisting after it receives the expected notice from Nasdaq. The company is working diligently to file its required financial statements, and ultimately to regain compliance with all of the Nasdaq Listing Rules and restore its listing as soon as practicable.

07:15 EST Veradigm to acquire ScienceIO for $140M in cash - Veradigm announced that it has signed a definitive agreement to acquire ScienceIO. The transaction has been unanimously approved by the Veradigm board and is expected to close as promptly as practicable following the satisfaction of customary closing conditions. Founded in 2019, ScienceIO is an AI platform and foundation model provider for healthcare. The transaction will be funded through cash on hand and is not subject to a financing condition. The purchase price to be paid for ScienceIO is $140M in cash, an aggregate of approximately $44M of which is deferred and substantially all of which is payable in installments on each of the first three anniversaries of the closing date.

07:15 EST Singing Machine generated record subscription sales for 2023 holiday season - The Singing Machine Company announced a significant new milestone in its partnership with leading music, media and technology company, Stingray Group, for their shared karaoke subscription service. For 2023, the Stingray-Singing Machine subscription service generated a record $3.28 million in gross sales, representing a 34.8% increase over the prior calendar year subscription sales. As part of its agreement with Stingray, the Company's profit share is calculated after deducting all costs of goods sold and expenses associated with maintaining this service. Consequently, the Company records net sales on music subscription sales at approximately 100% gross margin. "We are excited to report that subscription sales generated very strong results for the Company in 2023," commented Gary Atkinson, CEO of the Singing Machine. "We launched the first subscription- based music service in a pilot product offered only at Costco for the Christmas of 2021, and we have been very encouraged by the rapid acceptance of this service by consumers as we expanded the product placement in more retail locations globally."

07:14 EST Good Supply launches 'Juiced' cannabis pre-roll multi-packs across Canada - Tilray Brands announced the latest product releases from its Canadian cannabis brand, Good Supply. Good Supply's new infused GOOD SUPPLY JUICED lineup includes its first duo blunt multi-pack with the new 2x1g 'Cherry on Top' Blunts and a refreshed rotation of flavours in its new multi-strain 3x0.5g Discovery Pack. First making its appearance across retailers last summer, Good Supply's fruit-forward 'JUICED' infused pre-roll collection continues to expand with bold and fruity flavours drawing from Good Supply's acclaimed fan-favourite offerings. Good Supply's single-flavour pre-roll multi-packs, multi-flavour discovery pre-roll pack, and indulgent blunts feature a pairing of strain-specific flower with the fruit-flavoured extract of Good Supply's best-selling vapes.

07:11 EST ChampionX acquires Artificial Lift Performance, terms not disclosed - ChampionX Corporation announced the acquisition of Artificial Lift Performance Limited, a provider of advanced analytics solutions for enhancing oil and gas production performance. Based in Edinburgh, Scotland, ALP has extensive expertise in developing artificial lift optimization software designed to maximize production and extend the life of artificial lift equipment. Combining the capabilities of ALP's flagship Pump Checker software with ChampionX's XSPOC production optimization software delivers a comprehensive suite of advanced analytics across all major artificial lift types and chemical applications, enabling operators to gain invaluable insights and make informed decisions to meet their business objectives. XSPOC software, which was first introduced to the market in 2000 by the Theta production optimization business unit, has a long history in creating additional value from rod-lifted wells while Pump Checker analytics allow operators to maximize production performance and improve equipment reliability in electrical submersible pumping systems and gas lift systems.

07:09 EST Macy's to close 150 underproductive locations by 2026 - Macy's 'Bold New Chapter' strategy includes prioritizing three key areas to return to top-line growth: 1) Revitalizing the assortment to improve both relevance and value; 2) Modernizing the shopping environment to facilitate a convenient, easy, and frictionless customer experience across channels with continued focus on digital excellence; and 3) Focusing resources by closing approximately 150 underproductive locations, including approximately 50 by the end of the fiscal year, and prioritizing investment in approximately 350 go-forward locations and the continued expansion of small-format stores. The company said that approximately 15 Bloomingdale's nameplate stores and at least 30 new Bluemercury stores, along with roughly 30 Bluemercury remodels are anticipated to be opened in new and existing markets over the next three years. Across the organization, Macy's, Inc. plans to align operations to anticipated future omni-demand and deliver a more efficient operating model that will allow the organization to better serve customers. Beginning in 2025, Macy's, Inc. expects: Low-single-digit annual comparable Owned + Licensed + Marketplace sales growth; Annual SG&A dollar growth below the historic rate of inflation of 2%-3%; Annual Adjusted EBITDA dollar growth in the mid-single-digit range; Capital spend to be below 2024 levels; and Free cash flow to return to pre-pandemic levels.

07:09 EST Apellis expects cash to fund expenditures for 'foreseeable future' - As of December 31, 2023, Apellis had $351.2 million in cash and cash equivalents, compared to $551.8 million in cash and cash equivalents as of December 31, 2022. Apellis anticipates its cash balance, combined with cash anticipated to be generated from the unwind of the capped call transactions and from the sales of EMPAVELI and SYFOVRE, will be sufficient to fund its projected operating expenses and capital expenditures for the foreseeable future.

07:07 EST Bentley Systems boosts dividend a pennny to 6c per share - On February 21, the Company's Board of Directors increased by one cent the Company's regular quarterly dividend effective from the first quarter of 2024 and declared a 6c per share dividend for the first quarter of 2024. The cash dividend is payable on March 28 to all stockholders of record of Class A and Class B common stock as of the close of business on March 20.

07:05 EST Zentalis announces anticipated upcoming milestones - 1H 2024: Final results of Phase 1 azenosertib + chemotherapy trial in osteosarcoma. 2H 2024: Final results of Phase 1b azenosertib monotherapy trial in solid tumors; Topline data from Phase 1/2 azenosertib + PARP inhibitor and azenosertib monotherapy trial in platinum resistant ovarian cancer in partnership with GSK; Initial data from Phase 1 azenosertib + BEACON regimen trial in BRAF mutant metastatic colorectal cancer in partnership with Pfizer; Initial data from Phase 1 of azenosertib + ZN-d5 trial in R/R AML; Additional details on planned clinical trial of azenosertib in PSOC in the 1L maintenance setting. 1H 2025: Topline data from Phase 2 azenosertib monotherapy trial in platinum resistant high-grade serous ovarian cancer. 2H 2025: Topline data from Phase 2 azenosertib monotherapy trial in recurrent or persistent USC. 2025: Initiate clinical trial of azenosertib in PSOC in the 1L maintenance setting. 2026: First NDA for azenosertib in a gynecologic malignancy.

06:58 EST Macy's announces 'A Bold New Chapter' strategy - The company announced "A Bold New Chapter," a strategy designed to challenge the status quo to fundamentally reposition the company, enhance the customer experience, deliver growth and unlock shareholder value. Developed by the Macy's, Inc. leadership team, with the full support of the board of directors, the strategy aligns the organization to reinvigorate relationships with customers through improved shopping experiences with relevant assortments and compelling value. Reference Link

06:46 EST Westlake Epoxy receives ISCC PLUS certification at Duisburg, Germany site - Westlake announced that its Westlake Epoxy Duisburg, Germany manufacturing site has received the International Sustainability & Carbon Plus certification. The site received mass balance certification for its tracing and handling of sustainable materials in the production of epoxy specialty products. This is the second Westlake Epoxy site in Europe to receive ISCC PLUS certification. The goal is to achieve this certification for all Westlake Epoxy sites in Europe in the near future.

06:41 EST CGI Inc. awarded contract by Commonwealth of Massachusetts - CGI announced it has been awarded a contract by the Commonwealth of Massachusetts to deliver a financial management solution through CGI Advantage, a cloud-based platform that integrates financial data in a modern, unified platform. CGI will deploy a built-for-government solution to meet the Commonwealth's transformation goals, including increased data transparency and compliance, elimination of redundant activities, and improved business practices that allow the Commonwealth to interact with employees, contractors, and services providers more efficiently.

06:30 EST Nuvalent granted breakthrough therapy designation to NVL-520 by FDA - Nuvalent announced that the FDA has granted breakthrough therapy designation to NVL-520 for the treatment of patients with ROS1-positive metastatic non-small cell lung cancer, or NSCLC, who have been previously treated with two or more ROS1 tyrosine kinase inhibitors, or TKIs.

06:27 EST Cannae Holdings to wind down Management Services Agreement with Trasimene - Cannae Holdings has agreed to wind down its Management Services Agreement - MSA - with Trasimene Capital Management. Effective July 2, the MSA will be amended and restated to provide that Trasimene will receive a fixed management fee of $7.6M for each of the following three years, and a $20M termination fee, payable in three annual installments commencing on July 2, and no fees thereafter. As a result, Trasimene will not receive any incremental management fees or carried interest on investments made by the company on or after February 26, and beginning July 2, Trasimene will not receive any management fees or carried interest on any of the company's investments, other than the arrangements described above. William Foley, II will serve as the CEO, Chief Investment Officer, and Chairman of Cannae's Board of Directors and has entered into a three-year employment agreement. Ryan Caswell will cease to be a member of Trasimene as of July 2, and will continue to serve as the President of the company and has entered into a three-year employment agreement. Cannae expects these transactions to be marginally accretive to NAV per share upon the effective date of July 2.

06:19 EST BeiGene's Biologics License Application for tevimbra accepted by FDA - BeiGene announced that the FDA has accepted a Biologics License Application - BLA - for tevimbra, in combination with fluoropyrimidine- and platinum-containing chemotherapy, for the treatment of patients with locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma. The FDA's action date on the BLA is expected in December 2024. The filing is based on results from the global RATIONALE-305 trial. The study met its primary endpoint of overall survival of 15.0 months for patients treated with tevimbra in combination with investigator's choice of chemotherapy vs.12.9 months for patients treated with placebo plus chemotherapy, demonstrating a 20% reduction in the risk of death. Additionally, tevimbra plus chemotherapy was associated with a higher objective response rate and median duration of response vs. placebo plus chemotherapy. The safety profile for tevimbra in combination with chemotherapy was manageable and in line with the known safety profile of anti-PD-1 antibodies. Tevimbra was recently approved by the European Commission for the treatment of patients with advanced or metastatic esophageal squamous cell carcinoma after prior chemotherapy. The FDA is also reviewing a BLA for tevimbra as a first-line treatment for patients with unresectable, recurrent, locally advanced, or metastatic ESCC with a target action date in July 2024.

06:09 EST Constellation Energy declares quarterly dividend of 35.25c per share - The company's board of directors has declared a quarterly dividend of 35.25c per share on its common stock. The dividend is payable on Tuesday, March 19 to shareholders of record as of 5 p.m. Eastern time on Friday, March 8.

06:04 EST Esperion sees 2024 operating expenses $225M-$245M

05:34 EST Turkcell, Lynk Global jointly announceSat2Phone services contract - Lynk Global and Turkcell jointly announced the contract signing starting initial Sat2Phone services utilizing Lynk's "cell-towers-in-space." This collaboration is anticipated to complement network resiliency and mobile coverage across Turkiye, benefiting the local population, businesses and visitors.

05:27 EST Nokia selected by Rakuten to supply RAN solutions - Nokia (NOK) announced that it has been selected by Rakuten Mobile (RKUNY) to supply radio access network, or RAN, solutions from its comprehensive energy-efficient AirScale portfolio supporting the low 700MHz spectrum band. The move will see Rakuten Mobile deliver enhanced coverage, capacity, and network performance to its customers across its end-to-end fully virtualized, cloud native OpenRAN mobile network in Japan. Under the Rakuten Mobile deal, Nokia will supply equipment from its next generation AirScale radio access product portfolio powered by its ReefShark System-on-Chip (SoC) technology. Low band 4G spectrum enables wider area coverage and reaches deeper into buildings than higher frequencies and will allow Rakuten Mobile to bring 4G to even more customers.

05:12 EST Micron collaborates with Samsung on Galaxy S24 series - Micron (MU) announced that Samsung (SSNLF) has incorporated Micron's low-power double data rate 5X memory and Universal Flash Storage 4.0 mobile flash storage into select devices in the Samsung Galaxy S24 series, which introduces artificial intelligence, or AI, to mobile users around the world. The Galaxy S24 series is underpinned by Samsung's suite of generative AI tools, Galaxy AI, which helps amplify experiences from enabling barrier-free communication to maximizing creative freedom. As these data- and energy-intensive features push the limits of smartphones' hardware capabilities, Micron's LPDDR5X memory and UFS 4.0 storage provide critical high-performance capabilities and power efficiency to deliver these AI experiences at the edge. Select Samsung Galaxy S24 devices across the S24 Ultra, S24+ and S24 models are shipping with LPDDR5X and UFS 4.0 - the most recent innovations in Micron's mobile portfolio.